◆英語タイトル:Neurocrine Biosciences Inc (NBIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9829
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company has development and licencing partnerships with AbbVie Inc, BIAL–Portela & CA, S.A. and Mitsubishi Tanabe Pharma. Neurocrine is headquartered in San Diego, California, the US.
Neurocrine Biosciences Inc (NBIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10
Licensing Agreements 11
Neurocrine Biosciences Enters into Licensing Agreement with Bial 11
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12
Equity Offering 13
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 15
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Debt Offering 18
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc – Key Competitors 20
Neurocrine Biosciences Inc – Key Employees 21
Neurocrine Biosciences Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 05, 2018: Neurocrine Biosciences reports third quarter 2018 financial results 23
Jul 31, 2018: Neurocrine Biosciences Reports Second Quarter 2018 Financial Results 27
Apr 30, 2018: Neurocrine Biosciences Announces First Quarter 2018 Financial Results 29
Feb 13, 2018: Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 31
Jan 07, 2018: Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones 32
Nov 01, 2017: Neurocrine Biosciences Reports Third Quarter 2017 Results 33
Aug 03, 2017: Neurocrine Biosciences Reports Second Quarter 2017 Results 35
May 09, 2017: Neurocrine Biosciences Reports First Quarter 2017 Results 37
Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 40
Corporate Communications 43
Jan 07, 2018: Neurocrine Biosciences Announces Retirement of Christopher O’Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer 43
Nov 20, 2017: Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer 44
Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurocrine Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurocrine Biosciences and Jnana Therapeutics Enter into Agreement 10
Neurocrine Biosciences Enters into Licensing Agreement with Bial 11
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 12
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 13
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 15
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc, Key Competitors 20
Neurocrine Biosciences Inc, Key Employees 21
Neurocrine Biosciences Inc, Subsidiaries 22
List of Figures
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8